Literature DB >> 19104024

Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.

Maiken Cavling Arendrup1, Guillermo Garcia-Effron, Walter Buzina, Klaus Leth Mortensen, Nanna Reiter, Christian Lundin, Henrik Elvang Jensen, Cornelia Lass-Flörl, David S Perlin, Brita Bruun.   

Abstract

Caspofungin is used for the treatment of acute invasive candidiasis and as salvage treatment for invasive aspergillosis. We report characteristics of isolates of Candida albicans and Aspergillus fumigatus detected in a patient with breakthrough infection complicating severe gastrointestinal surgery and evaluate the capability of susceptibility methods to identify candin resistance. The susceptibility of C. albicans to caspofungin and anidulafungin was investigated by Etest, microdilution (European Committee on Antibiotic Susceptibility Testing [EUCAST] and CLSI), disk diffusion, agar dilution, and FKS1 sequencing and in a mouse model. Tissue was examined by immunohistochemistry, PCR, and sequencing for the presence of A. fumigatus and resistance mutations. The MICs for the C. albicans isolate were as follows: >32 microg/ml caspofungin and 0.5 microg/ml anidulafungin by Etest, 2 microg/ml caspofungin and 0.125 microg/ml anidulafungin by EUCAST methods, and 1 microg/ml caspofungin and 0.5 microg/ml anidulafungin by CLSI methods. Sequencing of the FKS1 gene revealed a mutation leading to an S645P substitution. Caspofungin and anidulafungin failed to reduce kidney CFU counts in animals inoculated with this isolate (P > 0.05 compared to untreated control animals), while both candins completely sterilized the kidneys in animals infected with a control isolate. Disk diffusion and agar dilution methods clearly separated the two isolates. Immunohistochemistry and sequencing confirmed the presence of A. fumigatus without FSK1 resistance mutations in liver and lung tissues. Breakthrough disseminated aspergillosis and candidiasis developed despite an absence of characteristic FKS1 resistance mutations in the Aspergillus isolates. EUCAST and CLSI methodology did not separate the candin-resistant clinical isolate from the sensitive control isolate as well as did the Etest and agar methods.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19104024      PMCID: PMC2650576          DOI: 10.1128/AAC.01292-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  47 in total

1.  Emergence of Candida tropicalis resistant to caspofungin.

Authors:  Tim Pasquale; Jon Rupert Tomada; Mahmoud Ghannoun; Joseph Dipersio; Hector Bonilla
Journal:  J Antimicrob Chemother       Date:  2007-11-16       Impact factor: 5.790

2.  Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST).

Authors:  M Cuenca-Estrella; M C Arendrup; E Chryssanthou; E Dannaoui; C Lass-Florl; P Sandven; A Velegraki; J L Rodriguez-Tudela
Journal:  Clin Microbiol Infect       Date:  2007-08-13       Impact factor: 8.067

3.  A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus.

Authors:  Eleusa Maria F Rocha; Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

Review 4.  Resistance to echinocandin-class antifungal drugs.

Authors:  David S Perlin
Journal:  Drug Resist Updat       Date:  2007-06-13       Impact factor: 18.500

5.  Effects of serum on in vitro susceptibility testing of echinocandins.

Authors:  Zekaver Odabasi; Victor Paetznick; John H Rex; Luis Ostrosky-Zeichner
Journal:  Antimicrob Agents Chemother       Date:  2007-09-04       Impact factor: 5.191

6.  Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.

Authors:  Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

7.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.

Authors:  R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent
Journal:  Crit Care Med       Date:  2008-01       Impact factor: 7.598

8.  In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

9.  Acquired resistance to echinocandins in Candida albicans: case report and review.

Authors:  Marie-Thérèse Baixench; Naji Aoun; Marie Desnos-Ollivier; Dea Garcia-Hermoso; Stéphane Bretagne; Sandrine Ramires; Christophe Piketty; Eric Dannaoui
Journal:  J Antimicrob Chemother       Date:  2007-04-27       Impact factor: 5.790

10.  One year prospective survey of Candida bloodstream infections in Scotland.

Authors:  Frank C Odds; Mary F Hanson; Amanda D Davidson; Mette D Jacobsen; Pauline Wright; Julie A Whyte; Neil A R Gow; Brian L Jones
Journal:  J Med Microbiol       Date:  2007-08       Impact factor: 2.472

View more
  55 in total

1.  Use of matrix-assisted laser desorption ionization-time of flight mass spectrometry for caspofungin susceptibility testing of Candida and Aspergillus species.

Authors:  Elena De Carolis; Antonietta Vella; Ada R Florio; Patrizia Posteraro; David S Perlin; Maurizio Sanguinetti; Brunella Posteraro
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

2.  Profiling the Aspergillus fumigatus proteome in response to caspofungin.

Authors:  Steven E Cagas; Mohit Raja Jain; Hong Li; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

3.  Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology.

Authors:  Ana Alastruey-Izquierdo; Alicia Gómez-López; Maiken C Arendrup; Cornelia Lass-Florl; William W Hope; David S Perlin; Juan L Rodriguez-Tudela; Manuel Cuenca-Estrella
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

4.  Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?

Authors:  A Espinel-Ingroff; M C Arendrup; M A Pfaller; L X Bonfietti; B Bustamante; E Canton; E Chryssanthou; M Cuenca-Estrella; E Dannaoui; A Fothergill; J Fuller; P Gaustad; G M Gonzalez; J Guarro; C Lass-Flörl; S R Lockhart; J F Meis; C B Moore; L Ostrosky-Zeichner; T Pelaez; S R B S Pukinskas; G St-Germain; M W Szeszs; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

5.  Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria.

Authors:  Michael A Pfaller; Daniel J Diekema; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2014-06-20       Impact factor: 5.948

6.  Transcriptional activation of heat shock protein 90 mediated via a proximal promoter region as trigger of caspofungin resistance in Aspergillus fumigatus.

Authors:  Frédéric Lamoth; Praveen R Juvvadi; Christopher Gehrke; Yohannes G Asfaw; William J Steinbach
Journal:  J Infect Dis       Date:  2013-10-04       Impact factor: 5.226

7.  In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods.

Authors:  Michael A Pfaller; Shawn A Messer; Mary R Motyl; Ronald N Jones; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

8.  Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence.

Authors:  Maiken Cavling Arendrup; Eleftheria Mavridou; Klaus Leth Mortensen; Eveline Snelders; Niels Frimodt-Møller; Humara Khan; Willem J G Melchers; Paul E Verweij
Journal:  PLoS One       Date:  2010-04-09       Impact factor: 3.240

9.  Fungal echinocandin resistance.

Authors:  Carol A Munro
Journal:  F1000 Biol Rep       Date:  2010-09-08

10.  Fungal echinocandin resistance.

Authors:  Louise A Walker; Neil A R Gow; Carol A Munro
Journal:  Fungal Genet Biol       Date:  2009-09-19       Impact factor: 3.495

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.